Sabrina Serani

New study reveals plixorafenib shows significant clinical benefits for thyroid cancer patients with BRAF mutations, offering hope for targeted therapies.

The FDA approved Bosaya and Aukelso biosimilars, enhancing options for cancer-related bone loss, including in patients with multiple myeloma.

The FDA fast-tracks CRB-701, an innovative ADC for advanced head and neck cancer, showing promising efficacy and safety in ongoing trials.

Ligufalimab receives FDA orphan drug designation for AML, showcasing promising efficacy and safety in treating hematologic malignancies and solid tumors.

Researchers explore innovative macrocyclic peptides to target small cell lung cancer, revealing promising therapeutic strategies for this aggressive disease.

FDA designates raludotatug deruxtecan as a breakthrough therapy for treating platinum-resistant ovarian cancers, enhancing patient care options.

Zipalertinib demonstrates significant efficacy and manageable safety in treating EGFR exon 20 insertion–mutated NSCLC, offering hope for patients.

Dordaviprone gains NCCN approval as a promising treatment for recurrent H3 K27M-mutant diffuse glioma, addressing urgent patient needs.

Promising results emerge from a clinical trial combining IDE397 and sacituzumab govitecan for treating MTAP-deleted urothelial cancer, showcasing safety and efficacy.

FDA accepts relacorilant and nab-paclitaxel for platinum-resistant ovarian cancer, showing promising survival benefits in recent trials.

FDA fast tracks GLSI-100 for HER2-positive breast cancer, promising new hope for patients with unmet medical needs. Discover its potential benefits.

The FDA approves selumetinib for young patients with neurofibromatosis type 1, offering hope for effective treatment of inoperable tumors.

The FDA approves Inlexzo, a groundbreaking treatment for bladder cancer, offering hope for patients unresponsive to traditional therapies.

FDA designates olomorasib and pembrolizumab as breakthrough therapy for advanced KRAS G12C-mutant lung cancer, showing promising response rates in trials.

FDA grants orphan drug designation to BA-101, a promising treatment for glioblastoma, aiming to improve outcomes in this challenging cancer.

Myeloma research faces funding uncertainties, yet collaboration and innovation drive optimism for breakthroughs in treatment and patient care.

New data highlightstaletrectinib's impressive efficacy and safety in treating ROS1-positive non–small cell lung cancer, offering hope for patients.

Interim results from the CAReS trial highlight ART27.13's potential to combat cancer-related weight loss, offering hope for effective treatment in CACS.

Pirtobrutinib shows significant promise in improving progression-free survival for patients with treatment-naive CLL/SLL, challenging traditional therapies.

A groundbreaking clinical trial explores botensilimab/balstilimab combination therapy, offering new hope for advanced colorectal cancer patients lacking effective immunotherapy options.

Researchers identify IL-6 as a key biomarker predicting resistance to CDK4/6 inhibitors in metastatic breast cancer, highlighting new therapeutic targets.

Rezolute streamlines the clinical pathway for ersodetug, expediting treatment for tumor hyperinsulinism and addressing urgent patient needs.

FDA fast-tracks CER-1236, a novel immunotherapy for acute myeloid leukemia, enhancing its development and potential market entry.

A groundbreaking study shows trastuzumab pamirtecan significantly improves progression-free survival in HER2-positive breast cancer patients, marking a major oncology advancement.

Lantern Pharma advances pediatric CNS cancer treatment with FDA guidance on LP-184 trial, targeting rare tumors and enhancing therapy with spironolactone.

Guardant Health's Shield test shows promising results in colorectal cancer screening, enhancing early detection and patient access with a noninvasive blood test.

Epcoritamab shows promise for outpatient treatment of relapsed DLBCL, enhancing patient access and quality of life while managing side effects effectively.

New research unveils a promising monoclonal antibody therapy targeting CALR mutations in essential thrombocythemia, aiming to improve patient outcomes.

The FDA approves Bildyos and Bilprevda, expanding treatment options for osteoporosis and cancer-related bone loss, enhancing patient access and affordability.

Zongertinib receives FDA breakthrough therapy designation for treating HER2-mutant non-small cell lung cancer, promising new hope for patients.